Prasugrel versus Ticagrelor in Acute Coronary Syndromes.

Whether prasugrel or ticagrelor should be the preferred P2Y12 inhibitor for patients with an acute coronary syndrome is uncertain.

Whether prasugrel or ticagrelor should be the preferred P2Y12 inhibitor for patients with an acute coronary syndrome is uncertain. We conducted a registry-based, open-label, stepped-wedge, cluster-randomized trial in Sweden involving adults who had undergone percutaneous…